Evaluation of miR-143 and miR-145 Expression in Tumors and Tumor Margins in Patients with Colorectal Cancer

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Biology, Urmia Branch, Islamic Azad University, Urmia, Iran

2 Associate Professor, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

3 Assistant Professor, Department of Biology, Urmia Branch, Islamic Azad University, Urmia, Iran

Abstract

Background: microRNAs are non-coding RNAs with about 22 nucleotides in length which modulate gene expression by binding to the gene target mRNA; they have eminent role as oncomiRs or microRNAs tumor suppressors. Changes in microRNAs expression have a radical role in pathobiology of different cancers. In this research, miR-143 and miR-145 expression in the tumor cells and tumor margins of patients with colorectal cancer were evaluated.Methods: Tumor cells and tumor margins were examined after being biopsied from 30 patients with colorectal cancer. Total RNA content was extracted from both tissue types with TRIzol reagent and then, complementary DNA (cDNA) of miRNAs were synthesized. microRNAs expression level was assessed through reverse transcription-polymerase chain reaction (RT-PCR) method using the SYBR Green. For statistical analysis, GraphPad Prism software was applied to compare the expression level of the microRNAs between tumor cells and tumor margins.Findings: The expression level of miR-143 and miR-145 were significantly lower in tumors compared to the margins (P < 0.0001 for both).Conclusion: Expression level of miR-143 and miR-145 were down-regulated in tumors compared to the margins. Lower expression level revealed that miR-143 and miR-145 can be utilized as diagnostic biomarkers in colorectal cancer. This may also introduce these microRNAs as colorectal cancer therapeutic targets.

Keywords

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
  2. Esna-ashari F, Sohrabi MR, Abadi AR, Mehrabian AA, Kolahi AA, Yavari P, et al . Colorectal cancer prevalence according to survival data in Iran in 2007. Pajouhesh Dar Pezeshki 2008; 32(3): 221-5. [In Persian].
  3. Berg M, Soreide K. Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci 2011; 12(12): 9426-39.
  4. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383(9927): 1490-502.
  5. Koga Y, Yamazaki N, Matsumura Y. New molecular diagnosis and screening methods for colorectal cancer using fecal protein, DNA and RNA. Expert Rev Mol Diagn 2014; 14(1): 107-20.
  6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
  7. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6(4): 259-69.
  8. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299(4): 425-36.
  9. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007; 26(5): 311-20.
  10. Iio A, Nakagawa Y, Hirata I, Naoe T, Akao Y. Identification of non-coding RNAs embracing microRNA-143/145 cluster. Mol Cancer 2010; 9: 136.
  11. Wang Y, Lee CG. MicroRNA and cancer--focus on apoptosis. J Cell Mol Med 2009; 13(1): 12-23.
  12. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103(7): 2257-61.
  13. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1(12): 882-91.
  14. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr., Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A 2006; 103(10): 3687-92.
  15. Bauer KM, Hummon AB. Effects of the miR-143/-145 microRNA cluster on the colon cancer proteome and transcriptome. J Proteome Res 2012; 11(9): 4744-54.
  16. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302(1): 1-12.
  17. Zhu H, Dougherty U, Robinson V, Mustafi R, Pekow J, Kupfer S, et al. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res 2011; 9(7): 960-75.
  18. Zhang F, Taipale M, Heiskanen A, Laiho M. Ectopic expression of Cdk6 circumvents transforming growth factor-beta mediated growth inhibition. Oncogene 2001; 20(41): 5888-96.
  19. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297(17): 1901-8.
  20. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26(30): 4442-52.
  21. Yang J, Zhang JY, Chen J, Chen C, Song XM, Xu Y, et al. Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies. World J Surg Oncol 2014; 12: 254.
  22. Ferreira AC, Robaina MC, Rezende LM, Severino P, Klumb CE. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101. Ann Hematol 2014; 93(6): 983-93.
  23. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, et al. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 2009; 26(1): 27-34.
  24. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282(45): 32582-90.
  25. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 2012; 12: 505.
Journal of Isfahan Medical School
Volume 35, Issue 452 - Serial Number 452
September and October 2017
Pages 1504-1508

Files

History

  • Receive Date: 07 March 2017
  • Revise Date: 23 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics